Molecular genetic investigations have made it clear that the development and progression of prostate cancer is associated with losses of genetic material in certain chromosomal arms. However, there are only few data about the question of whether the zonal location, a higher Gleason grade, or multifocality of the tumour have any in¯uence on the pattern of allelic losses.
Introduction
Adenocarcinoma is the single most important malignant tumour in the prostatic gland. Nevertheless, this entity comprises a wide spectrum of clinical behaviour, ranging from small, slow growing, indolent tumours to a rapidly progressing, life-threatening disease. Tumour volume, pathologic stage, and grade are the most commonly used prognostic parameters in predicting progression and recurrence after radical prostatectomy. 1 ± 3 Furthermore, the zonal location of the tumour might be relevant because prostate cancers arising in the ventromedial portion of the gland, called the transition zone, differ from the more frequent cancers in the peripheral zone with respect to morphology and clinical behaviour. 3 ± 8 In recent decades, much progress has been made in de®ning the genetic events that are involved in the development and progression of prostate cancer. From studies using restriction ± fragment ± length ± polymorphisms (RFLP) and microsatellite analyses, it has become evident that loss of genetic material at certain chromosomal arms is associated with this malignancy. Some of these genetic events, e.g., losses of the short arm of chromosome 8, are thought to occur early in the process of malignant transformation. 9, 10 Other deletions, such as losses of the long arm of chromosome 16, are more frequently observed in advanced tumours and could therefore be of prognostic importance. 11 ± 13 However, carcinoma in the prostatic gland often arises multifocally and each tumour focus might harbour different genetic alterations. Hitherto, only few studies investigated genetic heterogeneity in multiple individual tumor foci. 14 ± 18 Furthermore, to our knowledge, there are no investigations that systematically addressed the question whether the zonal location of prostatic cancers is associated with speci®c genotypic abnormalities.
In the present study, 48 prostate cancer foci from 32 radical prostatectomy specimens were investigated for the presence of relative allelic losses at chromosomes 8p, 10q, 11p, 13q, 16q, 17p, and 18q with a set of 20 microsatellite markers. The results were compared with the zonal location of the tumour foci and the presence of a Gleason grade 4 differentiation.
Materials and methods

Patients and tissues
Thirty-two radical retropubic prostatectomy (RRP) specimens were retrieved from the archives of the Institute of Pathology, University of Hamburg. Patients' ages ranged from 53 ± 73 y (median, 65 y). Surgery had been performed for clinically organ-con®ned prostate cancer at the Department of Urology, University of Hamburg. No patient had received preoperative endocrine treatment. The prostates were ®xed in 4% buffered formalin, and processed totally in 3 mm sections according to the Stanford protocol. 4 The 32 cases were selected for the presence of nearly equal amounts of tumour in the transition zone and in the peripheral zone and all slides were reviewed by a single pathologist (A.E.). On routine pathologic examination, nine tumours were organ-con®ned (pT2), 21 tumours displayed capsular penetration or seminal vesical in®ltration (pT3), and two cancers showed invasion of the bladder neck (pT4). The outlines of carcinomatous foci were marked with a pen on the H & E stained, whole-mount histological sections. By transferring the outlines of the gland and of all tumour foci from sequential slides on a piece of paper, a`tumour map' was generated for each case. Tumour volume was calculated by computer-based planimetry. 1 Foci of cancer were considered separate when divided by at least 3 mm non-neoplastic tissue and when no continuity was observed in sequential slides. The zonal location was determined according to the criteria de®ned by McNeal and coworkers. 4 Brie¯y, a tumour focus was assigned to the transition zone or to the peripheral zone when at least 70% of the tumour area was estimated to lie within that zone. Tumours with an indeterminate zonal origin were not included in this study. Tumour grade was determined according to the Gleason system. 2 A total of 48 tumour foci with various combined Gleason scores ranging from 4 to 10 were selected for microsatellite analysis. Twentyfour foci each were located in the peripheral zone and in the transition zone. Within one gland, only tumour foci that differed from another with regard to the zonal location or the Gleason score were investigated.
Microdissection and DNA preparation
For each case, three to ®ve sections parallel to the original H & E stained slide were adhered to glass slides, dewaxed, hydrated, and brie¯y stained with eosin. Using a sterile pulled Pasteur pipette, we removed tumour tissue from the slides by scratching and aspiration under direct light microscopic control (magni®cation 6 50) with a Zeiss Axiovert 1 10 microscope (Carl Zeiss Jena GmbH, Germany). After microdissection, these slides were also routinely stained with H & E and permanently mounted. Comparison with the original slides con®rmed the presence of over 80% tumour cells in the microdissected material. Tissue fragments were dissolved in TE buffer (10 mM Tris ± HCL, pH 7.4, 0.1 mM EDTA) that contained Proteinase K (Sigma-Aldrich, Deisenhofen, Germany) at 500 mg/ml. After overnight digestion, we extracted and puri®ed DNA with a commercially available kit (Cleanmix 1 , Labortechnik Fro È bel, Wasserburg, Germany). DNA of control tissue in each case was obtained from normal looking and hyperplastic prostatic tissue, carefully avoiding the inclusion of prostatic intraepithelial neoplasia (PIN).
Microsatellite analysis
We used the following 20 polymorphic microsatellite markers purchased from Research Genetics Inc. (Huntsville, AL, USA):
3), D18S58 (18q22.3 ± q23), and D18S64 (18q21.3).
PCR ampli®cations and gel electrophoresis were performed as previously described. 19 Brie¯y, reaction mixtures contained 50 ± 100 ng of genomic DNA, each primer at 1 mM; dATP, dGTP, dTTP, and dCTP (Boehringer Mannheim, Germany) each at 200 mM; 0.8 units of Taq DNA polymerase (Appligene Oncor, Heidelberg, Germany), and 1 6 reaction buffer in a ®nal volume of 20 ml. DNA was ampli®ed by PCR in 35 cycles with annealing temperature optimised for each pair of primers. PCR products were electrophoresed through 6% denaturing polyacrylamide gels (Sequigel 1 , Biozym, Oldendorf, Germany), silver-stained essentially as described elsewhere, 20 transferred on ®lter paper, and vacuum-dried.
Evaluation
We determined allelic loss by comparing the intensity of heterozygous alleles of the matched tumour DNA and control DNA. In most cases, loss of one allele from tumour tissue was not complete; a faint band could still be observed, probably representing contaminating normal (stromal or in¯ammatory) cells. Relative differ-ences in allelic dosage were measured with scanning densitometry based on commercially available software (SigmaGel 1.05 1 , SPSS Inc., Chicago, IL, USA). Relative allelic loss was considered to be present when the relative intensity of the two alleles in tumour DNA differed from the relative intensity in control tissue DNA by a factor of at least 1.5, a cut-off value that has also been used by many other investigators. 12,21 ± 25 Cases where only one allele was visible in normal as well as in tumour tissue most probably were homozygous for that particular marker and were designated as being`not informative'. Band shifts of one allele from cancerous tissue, indicating microsatellite instability, were also recorded. Experiments that yielded equivocal results were repeated.
Statistics
Statistical calculations were performed with commercially available software (InStat 2.02 1 , GraphPad, San Diego, CA, USA). Two-by-two contingency tables comparing the presence or absence of allelic loss with the zonal location or the presence of high-grade tumour were calculated with Fisher's exact test. P values`0.05 were considered signi®cant.
Results
A synopsis of the preoperative prostate speci®c antigen (PSA) values, tumour volumes, Gleason grades, zonal location, and the results of the microsatellite analysis of the 32 prostates containing 48 tumour foci is given in Figure 1 . Preoperative PSA values ranged from 3.4 ng/ml to 120 ng/ml (median, 14.7 ng/ml) and total tumour volumes ranged from 1.1 ± 44.8 cm 3 (median, 13.3 cm 3 ). Twenty-four tumour foci each were located in the peripheral zone and in the transition zone. Overall, microsatellite analysis was successful in nearly 98% of assays and only 20 assays yielded no ampli®cation product, even at repeated experiments.
All 32 cases were informative for at least one of the four markers mapping at chromosome 8p. Twenty of these demonstrated at least focal allelic losses with one or more marker (62.5%). Figure 2 illustrates allelic loss at the marker NEFL in a peripheral tumour focus of case 21. At 10q, three cases were not informative for any of the three markers used. Of the remaining 29 cases, ®ve showed allelic losses (17.2%). Two cases displayed band shifts at D10S196 and D10S215, indicating microsatellite instability.
At 11p, two markers were suf®cient to get informative band patterns for all but one case. Allelic loss was only observed in one focus containing Gleason grades 3 3 of case 31. Interestingly, a second tumour focus of the same case containing a pure Gleason 4 4 pattern showed no allelic loss but microsatellite instability. Figure 2 illustrates the band pattern of that case at D11S554.
Two markers were also suf®cient to get informative results for all 32 cases at 13q. Six cases showed allelic losses in one or two tumour foci (18.8% of cases). In Figure 2 , allelic losses at D13S263 can be seen in case 12, a transition zone tumour, and in case 13, whereas case 14 demonstrates retention of heterozygosity.
At 16q, 30 cases were informative for the three markers employed and 12 of these (40%) demonstrated focal allelic losses. Figure 2 illustrates allelic loss in a tumour focus of case 9 at D16S398.
Only three allelic losses were observed in 31 informative cases at 17p (9.7%). Allelic loss at D17S786 in case 13 is also shown in Figure 2 .
At 18q, all but one case yielded informative results. We found focal allelic losses in seven cases (22.6%).
Of the 32 prostates examined, 14 contained different tumour foci with regard to zonal location and/or Gleason grade. In 12 prostates, two separate tumour foci were investigated, and in two other prostates, three different foci were subjected to microsatellite analysis. Of the resulting 48 tumour foci, 24 were located in the transition zone and 16 of these (66.7%) displayed allelic losses with at least one marker. Sixteen focal allelic losses were also observed in the 24 tumour foci from the peripheral zone. There was also no statistically signi®cant difference when the frequencies of allelic losses at each of the seven chromosomal arms were compared with the zonal location of the tumour.
Twenty-eight of the 48 tumour foci were well differentiated and displayed only small-or medium-sized acinar structures (Gleason grades 3 or 2) . The other 20 foci contained high-grade carcinoma, as de®ned by the presence of a Gleason 4 or 5 pattern. Of the latter, 15 foci showed allelic losses with at least one marker (75%), 
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Only at 13q was there a correlation between the frequency of allelic losses and the presence of high grade tumour that was of borderline signi®cance (P 0.047, Fisher's exact test). Table 1 summarises the frequencies of allelic losses with regard to the zonal location and tumour grade. Of the 14 cases with more than one tumour focus, 12 displayed genetic heterogeneity, as indicated by different patterns of focal allelic losses within a case. This phenomenon could be observed in tumour foci that differed in the zonal location only (cases 17 and 27), and in tumour foci that contained different Gleason grades. Examples of such heterogeneity are illustrated in Figure 2, cases 9, 12, 21 , and 31.
Discussion
In the present study, 32 radical prostatectomy specimens containing 48 cancer foci were investigated for the presence of relative allelic losses at several chromosomal arms. We performed microdissection of paraf®n-embedded tumour tissue to minimise`contamination' with normal DNA and used a non-radioactive microsatellite assay as previously described. 18 ± 20 The most frequent alterations were found at chromosome 8p (62.5% of cases), followed by 16q, 18q, 13q, and 10q (40%, 22.6%, 18.8% and 17.2% of informative cases, respectively). Allelic losses were less frequent at 17p (9.7% of cases), and only one tumour displayed allelic loss at 11p. In 14 prostates, more than one tumour focus was investigated and 12 of these displayed a heterogeneous pattern of allelic loss for at least one marker. There was no strong correlation between the frequency of allelic losses at any locus investigated and the presence of high-grade (Gleason grade 4) tumour. With regard to the zonal location, no signi®cant differences could be found between tumour foci located in the transition zone and in the peripheral zone of the gland.
Prostate carcinoma is the most commonly diagnosed non-cutaneous cancer and the second leading cause of cancer death in the adult male in the USA 26 and in other Western nations. Radical prostatectomy offers a curative approach for clinically organ-con®ned tumours, but about 25% of patients suffer from tumour recurrence within the ®rst two years after prostatectomy, as detected by sensitive PSA assays. 27 Tumour volume, grade, and pathological stage are well accepted prognostic parameters that can be gathered by pathologists from prostatectomy specimens. 1 There is also evidence that the extent of tumour multifocality, which is a frequent event in prostate carcinoma, might be of prognostic relevance. 28, 29 Furthermore, the zonal location of the tumour seems to be an important parameter, as morphologic and biologic differences have been reported between tumours in the transition zone and the more frequent cancers located in the peripheral zone. To begin with, putative precursor lesions are different in both zones. In the peripheral zone, PIN is an accepted premalignant condition. 30 However, this entity is rare in the transition zone. Here, on the other hand, exists a lesion called`adenosis' or`atypical adenomatous hyperplasia' 
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(AAH), which morphologically resembles well-differentiated carcinoma, but whose preneoplasic nature is still under debate. 31, 32 Prostate carcinomas arising in the transition zone are often well differentiated and organcon®ned despite a large tumour volume 3 ± 5,8 and a signi®cantly lower proliferation index was reported in one study. 6 For these reasons, tumours arising in the transition zone of the prostate are thought to follow a less aggressive course than the more common peripheralzone cancers. 8 Loss of genetic material at chromosome 8p in prostate cancer has been documented in numerous investigations and by different methods. With the use of microsatellite analysis, reported frequencies of relative allelic losses at that locus range from 29% to 90.6%. 9,10,14,21,23,24,33 ± 36 The frequency of detected alterations by this method clearly depends on the number of microsatellite markers employed and the de®nition of allelic loss. With the use of four microsatellite markers at chromosome 8p and an imbalance factor of 1.5 as a cut-off value our results come quite close to two larger studies using the same imbalance factor. 23, 24 Mapping studies indicate that there may be at least two distinct regions of allelic loss at chromosome 8p. 36 Allelic losses at 8p were also frequently observed in PIN lesions, suggesting that alteration to be an early event in the development of prostate cancer. 9, 10, 14 Chromosome 10q losses have been described in frequencies of about 30% in prostate cancers. 23,24,37 ± 39 The PTEN/MMAC1 gene located on 10q23 and the Mxi1 gene on 10q25 are candidate tumour suppressor genes in the prostate. 40 ± 42 Using three microsatellite markers that map to region 10q11.2 ± q25, we only found 17.2% of prostates to contain allelic losses. However, the highest frequencies reported in the literature came from advanced or metastatic tumour samples, 41, 43 and these stages might be underrepresented in the present investigation. The KAI1 gene is a metastasis suppressor gene located on chromosome 11p11.2. Down-regulation of the KAI1 protein expression is a frequent event in the progression of prostate cancer. 44 However, loss of genetic material at 11p does not seem to play an important role in down-regulation of the KAI1 gene, as low frequencies of allelic imbalance at that locus have been found by two investigators 23, 24 and in the present study. Interestingly, Kawana et al also observed allelic loss at 11p in a low rate in clinically localised prostate cancer, but in a higher rate of 33% in advanced autopsy cases and in 70% of metastases. 45 Chromsome locus 13q14 harbours the retinoblastoma susceptibility (RB1) gene, a tumour suppressor gene frequently deleted in a number of tumour types, including prostate cancer. Allelic loss at that locus has been reported at frequencies of about 30%. 23, 46, 47 Another tumour suppressor gene, the BRCA2 gene, is located in a more centromeric position on chromosome 13q. This gene probably also plays a role in prostate cancer, as could be shown in a large study that used immunohistochemistry in combination with microsatellite analysis. 48 Allelic loss at 16q is also a frequent event in prostate cancers, reported frequencies ranging from 30% to 56%. 11 ± 14,23 ± 25,37,49 The CDH1 gene, which is located on 16q22.1 and encodes the epithelial cell adhesion molecule E-cadherin, might be the target of the observed deletions. 12, 25, 49 Furthermore, additional sites of deletion more telomeric to 16q22 have been reported and it seems as if the long arm of chromosome 16 harbours multiple tumour suppressor genes. 12, 13, 25 Some of these investigators found a signi®cant correlation between 16q losses and metastatic and aggressive behaviour of prostate cancers. 11 ± 13 In the present study, allelic imbalance at 16q was not signi®cantly associated with higher Gleason scores, which is in concordance with the ®ndings by Godfrey and co-workers. 25 Allelic losses at 17p and mutations of the p53 gene at 17p13.1 are some of the most common genetic events in solid tumours. However, in prostate cancers, alterations of the p53 gene seem to occur less often and later in the process of tumour progression. 23, 37, 39, 50, 51 This is con®rmed by the present study where only 9.7% of prostate cancers displayed focal allelic loss. Chromosomal region 18q has been reported to undergo allelic loss in 17% to 39%. 23, 24, 35, 37 We observed allelic loss at that locus in 22.6% of cases. The DCC (deleted in colorectal carcinoma) gene is a putative target at that chromosomal arm.
Microsatellite instability, i.e. instability of the length of dinucleotide sequences resulting in band shifts, is regarded as an indicator of defect DNA mismatch repair function. Whereas this kind of genetic defect seems to play an important role in some forms of familial colon cancer, it is infrequent in prostate cancer according to a study by Terrell and coworkers, 52 and to our results.
In the present study, the 32 cases were selected for the tumour location rather than for homogenous Gleason grades. Therefore, the comparison between allelic losses and Gleason grade was limited to the presence or absence of high-grade tumour. There was a trend but no statistically signi®cant correlation between overall allelic 11, 13 whereas Gray and coworkers found no correlation between 10q losses and tumour grade. 40 Thus, the association between genetic changes and tumour grade is still controversial, but it might partly depend on the speci®c grading system applied. It seems plausible that genetic changes correlate with a grading system that measures nuclear abnormalities rather than with the Gleason system, which is based on the architecture of neoplastic glands. Tumour multiplicity and morphologic heterogeneity are intrinsic features of prostatic carcinoma. 28, 29, 53 There is evidence that tumour heterogeneity also exists on the genetic level. Using interphase cytogenetics, we and others found that numerical chromosomal aberrations are unevenly distributed among different tumour foci within the prostatic gland. 7, 15 Marked intra-tumour heterogeneity was also found in a case of metastatic carcinoma by comparative genomic hybridisation. 54 With microsatellite analysis, different patterns of allelic loss at 8p and 17q were observed among different tumour foci and PIN areas. 9, 10, 16, 17 In a larger study with 25 microsatellite markers, Hugel and Wernert also found a high rate of intratumoral heterogeneity. 18 In the present study, of the 14 cases with more than one tumour foci, allelic loss patterns in 12 cases differed by at least one marker. This high prevalence of genetic heterogeneity has to be taken into consideration when the usefulness of genetic markers in preoperative core biopsies is discussed.
Hitherto, the in¯uence of the zonal location of prostatic cancers on clinical outcome after surgical therapy has not been thoroughly investigated. The studies mentioned above point toward some differences in biology and morphology between carcinomas arising in the transition zone and in the peripheral zone. However, it is not yet clear whether anatomic reasons alone can account for all these differences. Genetically, numerical chromosomal aberrations seem to occur later in the progression of cancers located in the transition zone as compared to peripheral-zone cancers. 6, 7, 55 Using microsatellite analysis with markers for chromosomes 8q and 13q, Crundwell and co-workers investigated genetic alterations in 26 incidentally diagnosed transition zone cancers. 56 They found allelic losses at 8p in 37% of cases and a surprisingly high rate of 50% at 13q. The authors speculated that there might be qualitative differences between tumours in the transition zone and in the peripheral zone. But, to our knowledge, the present study is the ®rst that systematically compared microsatellite alterations in prostate cancers with regard to the zonal location of tumour loci. With 20 microsatellite markers mapping to seven chromosomal regions that are supposed to play an important role in prostate cancer development and progression, we found no signi®cant differences between transition zoneand peripheral zone-tumours. There are, however, other chromosomal regions that also seem to be involved, e.g. 7q, 12p and 17q. 22, 24, 57 Besides, other genetic and epigenetic events, such as alterations in the androgen receptor gene or in the regulation of its expression, may differ between cancers in the different zones of the prostate.
In summary, our results support the concept of genetic heterogeneity in prostate carcinomas. However, there is no evidence that speci®c allelic losses are strongly associated with a particular zonal location of prostate cancer or with the presence of high-grade carcinoma.
